UnitedHealth Group's Medicare Advantage Boost Masks Overvaluation Fears

UnitedHealth Group (UNH) has seen its stock price rally sharply over the past year, driven by optimism around Medicare Advantage economics and higher operating earnings. The company's Optum units are also benefiting from increased use of AI tools to trim administrative costs.

The current share price is $412.75, with a 1-year total shareholder return of 72.43%. This has led some investors to question whether the stock is still fairly valued, given its recent performance.

According to one popular narrative on UnitedHealth Group, the fair value is $395, which would put the stock at around 4.5% overvalued. However, this view is based on a reset in margins, steadier revenue growth, and an earnings profile that looks different from a plain insurer.

The narrative also highlights the value of Optum's data and services engine, which is treated as a 'legacy utility' multiple when buying UNH at a 13x-15x Forward P/E. However, there are risks to this narrative, including tighter Medicare Advantage rules or slower benefits from AI and data projects.

An alternative view on UnitedHealth Group comes from market ratios, which suggest that the stock trades at 26.5x earnings, slightly higher than the US Healthcare industry but below the peer average of 28.8x and a fair ratio of 40.3x.